Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Allogeneic Vaccine for High Risk Melanoma
NCT01861938Phase 3Withdrawn
- Sponsor
- Hadassah Medical Organization
- Start
- Mar 2017
- Primary completion
- Mar 2019
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
01
Overview
Phase 3, open-label, single-arm trial of A2/4-1BBL in melanoma, sponsored by Hadassah Medical Organization. Primary endpoint: Number of adverse effects at 20 weeks. Planned start Mar 2017; status: withdrawn.
02
Drugs
A2/4-1BBL
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01861938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861938.